Alkermes (ALKS) Issues FY17 Earnings Guidance
Alkermes (NASDAQ:ALKS) issued an update on its FY17 earnings guidance on Wednesday morning. The company provided EPS guidance of $0.03-0.22 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.12. The company issued revenue guidance of $870-900 million, compared to the consensus revenue estimate of $882.79 million.
Shares of Alkermes (NASDAQ:ALKS) opened at $56.64 on Wednesday. The company has a quick ratio of 2.72, a current ratio of 3.05 and a debt-to-equity ratio of 0.23. Alkermes has a 1-year low of $46.42 and a 1-year high of $63.40. The company has a market capitalization of $8,710.00, a price-to-earnings ratio of -51.03 and a beta of 2.13.
Alkermes (NASDAQ:ALKS) last released its earnings results on Thursday, October 26th. The company reported $0.03 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.01) by $0.04. Alkermes had a negative return on equity of 7.27% and a negative net margin of 20.12%. The business had revenue of $217.40 million for the quarter, compared to the consensus estimate of $231.29 million. During the same period in the previous year, the company posted ($0.09) earnings per share. The company’s revenue for the quarter was up 20.6% compared to the same quarter last year. sell-side analysts anticipate that Alkermes will post -0.59 EPS for the current fiscal year.
In related news, SVP Michael J. Landine sold 15,000 shares of the company’s stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $48.71, for a total transaction of $730,650.00. Following the completion of the sale, the senior vice president now owns 178,693 shares in the company, valued at $8,704,136.03. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Richard F. Pops sold 50,000 shares of the company’s stock in a transaction on Thursday, November 2nd. The shares were sold at an average price of $48.87, for a total value of $2,443,500.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 136,417 shares of company stock worth $7,259,391. Corporate insiders own 5.34% of the company’s stock.
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.